TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy

Tumor necrosis factor superfamily member 14 (LIGHT) has been in pre-clinical development for over a decade and shows promise as a modality of enhancing treatment approaches in the field of cancer immunotherapy. To date, LIGHT has been used to combat cancer in multiple tumor models where it can be co...

Descripción completa

Detalles Bibliográficos
Autores principales: Skeate, Joseph G., Otsmaa, Mikk E., Prins, Ruben, Fernandez, Daniel J., Da Silva, Diane M., Kast, W. Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243824/
https://www.ncbi.nlm.nih.gov/pubmed/32499782
http://dx.doi.org/10.3389/fimmu.2020.00922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243824/
https://www.ncbi.nlm.nih.gov/pubmed/32499782
http://dx.doi.org/10.3389/fimmu.2020.00922

Ejemplares similares